Summary of professor An Ayue’s experience in treating familial adenomatous polyposis with the theory of consolidating body resistance and eliminating accumulation
WANG Xi FENG Yuening WANG Chunhui FENG Dayong BAI Zhiyong AN Ayue
Department of Anorectal, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Abstract：Familial adenomatous polyposis has a high cancer transformation rate, it is one of thorny diseases. Professor An Ayue combines disease differentiation with syndrome differentiation and proposes the theory of “consolidating body resistance the foundation and eliminating accumulation” in treating familial adenomatous polyposis. He belives that the location of familial adenomatous polyposis is in the intestinum crassum， closely related to the liver, spleen, and kidney. The pathogenesis of familial adenomatous polyposis is dificiency in origin and excess in superficiality. Deficiency in origin is based on kidney deficiency, spleen deficiency and liver stagnation. Excess in superficiality is mainly due to the accumulation of phlegm and blood stasis, as well as the heat in the colon and organs. In terms of treatment principles, he mainly focuses on tonifying the kidney and filling the essence, strengthening the spleen and regulating the liver, resolving phlegm and blood stasis, and clearing heat and dispersing nodules. He emphasizes the importance of supporting the right and eliminating evil, and treating both symptoms and root causes simultaneously, and combining disease and syndrome based on the patient’s condition, adding or subtracting with the syndrome.
王茜 冯月宁 王春晖 冯大勇 白志勇 安阿玥. 安阿玥教授运用固本消积法治疗家族性腺瘤性息肉病的经验[J]. 中国医药导报, 2023, 20(31): 150-153.
WANG Xi FENG Yuening WANG Chunhui FENG Dayong BAI Zhiyong AN Ayue. Summary of professor An Ayue’s experience in treating familial adenomatous polyposis with the theory of consolidating body resistance and eliminating accumulation. 中国医药导报, 2023, 20(31): 150-153.
[1] 陈春燕，魏娟，蒋康，等.家族性腺瘤性息肉病家系的APC基因突变分析[J].医学研究生学报，2022，35（12）：1279. [2] 杨志林，霍景山，贺友.APC基因突变型家族性腺瘤性息肉病多部位癌变一例[J].临床外科杂志，2019，27（5）：393-394. [3] Pérez-Cuadrado-Robles E，Piessevaux H，Moreels TG，et al. Combined excision and ablation of ampullary tumors with biliary or pancreatic intraductal extension is effective even in malignant neoplasms [J]. United European Gastroenterology J，2019，7（3）：369-376. [4] 王丹，杨晶，张昭，等.家族性腺瘤性息肉病最新研究进展[J].中国肛肠病杂志，2018，38（9）：62-65. [5] 赵子夜，汪昭明，于恩达，等.Mut YH相关息肉病患者的基因变异特点分析[J].结直肠肛门外科，2023，29（2）：144. [6] 杨翠萍，杨晓金，李婷，等.舒林酸联合双歧杆菌三联活菌治疗家族性腺瘤性息肉病的作用及其机制初探[J].中华消化病与影像杂志，2022，12（5），286. [7] Monahan KJ，Bradshaw N，Doiwani S，et al. Hereditary CRC guidelines eDelphi consensus group. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology（BSG）/Association of coloproctology of Great Britain and Ireland（ACPGBI）/United Kingdom Cancer Genetics Group（UKCCG） [J]. Gut，2020，69（3）：411- 444. [8] Waddell WR，Loughry RW. Sulindac for polyposis of the colon [J]. J Surg Oncol，1983，24（1）：83-87. [9] Lynch PM，Ayers GD，Hawk E，et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis [J]. Am J Gastroenterol，2010，105（6）：1437-1443. [10] Ishikawa H，Wakabayashi K，Suzuki S，et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis：double-blind，randomized clinical trial [J]. Cancer Med，2013， 2（1）：50- 56. [11] Samadder NJ，Kuwada SK，Boucher KM，et al. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis：Secondary Analysis of a Randomized Clinical Trial [J]. JAMA Oncol，2018， 4（5）：671-677. [12] Ishikawa H，Mutoh M，Sato Y，et al. Chemoprevention with low-dose aspirin，mesalazine，or both in patients with familial adenomatous polyposis without previous colectomy （J-FAPP Study Ⅳ）：a multicentre， double-blind，randomised，two-by-two factorial design trial [J]. Lancet Gastroenterol Hepatol，2021，6（6）：474-481. [13] 葛赛，王晰程.家族性腺瘤性息肉病的诊疗进展[J].肿瘤综合治疗电子杂志，2022，8（1）：108-110. [14] Ishikawa H，Mutohm，Abe T，et al. Utility of mesal azine in familial adenomatous palyposis：clinical report of reduction of polypsize in patients with ulcerative colitis， and safety examination infami lial adenomatous polyposis patients [J]. Pharmac ology，2019，104（1/2）：51-56. [15] Samadder NJ，NekPason DW，Boucher KM，et al. Effect of sul- indac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis：a randomized clinical trial [J]. JAMA，2016， 315（12）：1266-1275. [16] Liu S，Barry EL，Baron JA，et al. Effects of supplemental calcium and vitamin D on the APC/p- catenin pathway in the nor-mal colorectal mucosa of color ectal adenoma patients [J]. MolCarcinog，2017，56（2）：412-424. [17] 马树梅，李薇，杜冠潮，等.大肠息肉的中医病名探讨[J].现代中医临床，2020，27（2）：48. [18] 安阿玥.现代中医肛肠病学[M].北京：中国医药科技出版社，2019：573. [19] 方媛，张宇，刘伟臻，等.家族性腺瘤性息肉病的诊疗进展[J].中国肿瘤外科杂志，2022，14（4）：407-408. [20] 霍清萍，孔林.家族性腺瘤性息肉病治验1则[J].上海中医药杂志，2008，42（9）：12-13. [21] 崔泽华，刘建平，徐伟超，等.国医大师李佃贵基于浊毒理论治疗结肠息肉思路[J].中华中医药杂志，2023，38（2）：634-636. [22] 王少墨，王秀薇，姚怡，等.王庆其治疗大肠息肉经验[J].中医杂志，2016，57（15）：1278-1280. [23] 任霞，赵智强.赵智强教授辨治结肠腺瘤样息肉学术经验初探[J].浙江中医药大学学报，2017，41（1）：75-77. [24] 雷昕昀，赵先明，梁咏欣.岭南地区结肠癌患者中医体质类型研究[J].广州中医药大学学报，2020，37（10）：1850-1853. [25] 郑翊轩，白光.慢性萎缩性胃炎患者中医体质类型分布特点[J].临床军医杂志，2020，48（72）：804-805. [26] 王单单，郭丽娜，田会东，等.基于网络药理学的白花蛇舌草、半枝莲对治疗大肠癌的作用机制研究[J].天津中医药，2019，36（12）：1227-1233. [27] 陈淑玲，韩亮.败酱草的现代研究进展[J].广东药科大学学报，2017，33（6）：816-821. [28] 楚永庆，陈霞，李力，等.160例大肠息肉患者中医证型与中医体质分布规律研宄[J].中医杂志，2021，62（11）：966-970.
2023, Vol. 20 
京公网安备 11010502046598号